← Browse by Condition
Medical Condition

igg4 related diseases

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for igg4 related diseases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — igg4 related diseases Clinical Trials

How many clinical trials are currently recruiting for igg4 related diseases?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for igg4 related diseases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for igg4 related diseases?
igg4 related diseases research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a igg4 related diseases clinical trial?
Eligibility criteria for igg4 related diseases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Peking University People's Hospital 1 trial
Luo Yaping 1 trial

Recruiting Clinical Trials

NCT06794008 Phase 2
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Enrollment
50 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT07104058
Recruiting
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
Enrollment
46 pts
Location
China
Sponsor
Luo Yaping
View Trial →

Related Conditions

systemic lupus erythematosus (1) inflammatory myopathy (1) systemic sclerosis ssc (1) anca associated vasculitis (1) antiphospholipid syndrome (1) acquired thrombotic thrombocytopenic purpura (1) behcet disease (1) sjogren syndrome (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology